Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2036-07-31 | Direct | 7,500 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 7,500 · Balance 7,500 F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 20:10 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (Right to Buy · Derivative | 7,500 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001213900-26-085188 · ownership.xml · derivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2036-07-31 F1 · derivative.exercise_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. F1 · derivative.expiration_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 41,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001213900-25-091096 · ownership.xml · derivative · entry 2 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Voting Common Stock · 41,000 shares Expires 2030-03-22 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseVoting Common Stock | 41,000 | $2.43 | $99,630.00 |
DisclosureSEC source: 0001213900-25-091096 · ownership.xml · nonDerivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,901 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 20:24 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001213900-25-061500 · ownership.xml · derivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2035-07-03 F1 · shares: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:25 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001213900-24-051411 · ownership.xml · derivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2034-06-06 Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 22:43 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001213900-23-047570 · ownership.xml · derivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Voting Common Stock · 47,000 shares Expires 2033-06-07 Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 00:03 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 29,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-063943 · ownership.xml · nonDerivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,012 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:03 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 78,045 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014567 · ownership.xml · derivative · entry 1 Shizuru Judith Anne · CIK 0001883000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,045 Underlying: Voting Common Stock · 78,045 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on December 7, 2022, and 1/3rd of the shares subject to the option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.